<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04707261</url>
  </required_header>
  <id_info>
    <org_study_id>2020/12/01</org_study_id>
    <nct_id>NCT04707261</nct_id>
  </id_info>
  <brief_title>Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)</brief_title>
  <acronym>ADIDAS</acronym>
  <official_title>A Prospective, Randomized, Double-blind, Multicenter Study on the Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiangtan Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ZhuZhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xiangtan Central Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate the hemoglobin change and association&#xD;
      between hemoglobin change and readmissions due to heart failure, and all-cause death in&#xD;
      patients with heart failure treated with dapagliflozin or placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Description Brief Summary: The primary objective of this study is to investigate the&#xD;
      hemoglobin change and association between hemoglobin change and readmissions due to heart&#xD;
      failure, and all-cause death in patients with heart failure treated with dapagliflozin or&#xD;
      placebo.&#xD;
&#xD;
      Detailed Description: Heart failure is one of the most serious health concerns in the world,&#xD;
      and it also remains the most common reason for hospitalization in older individuals. In&#xD;
      patients with heart failure, anemia is associated with an increased risk of hospitalization&#xD;
      and all-cause mortality. The DAPA-HF trial demonstrated that dapagliflozin was able to reduce&#xD;
      the risk of worsening heart failure (HF) events and cardiovascular death comparing to placebo&#xD;
      in patients with reduced ejection fraction on top of standard of care.&#xD;
&#xD;
      This is an investigator-initiated, interventional, prospective, double-blind study. The&#xD;
      primary objective is to investigate whether anemia correction is one of the prerequisites and&#xD;
      determinants related to the beneficial effects of dapagliflozin in patients with heart&#xD;
      failure. Impact of dapagliflozin treatment on hemoglobin level, heart failure-related&#xD;
      readmission and all-cause death will be observed in comparison with placebo in heart failure&#xD;
      patients receiving guideline recommended standard therapy during the 3months, 6 months and 1&#xD;
      year follow up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite number of hospital admissions for Heart Failure (HF) and all-cause death</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score</measure>
    <time_frame>Baselin, 3 months, 6 months, and 1 year</time_frame>
    <description>The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6-minute walk distance (6MWD)</measure>
    <time_frame>Baselin, 3 months, 6 months, and 1 year</time_frame>
    <description>This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin</measure>
    <time_frame>Baselin, 3 months, 6 months, and 1 year</time_frame>
    <description>g/L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1990</enrollment>
  <condition>Anemia</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin with standard-of-care therapies for heart failure, including sacubitril/valsartan or ACEI/ARB, beta-blocker, MRA, ICD and CRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard-of-care therapies for heart failure, including sacubitril/valsartan or ACEI/ARB, beta-blocker, MRA, ICD and CRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Participants will receive dapagliflozin 10 mg once daily</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <other_name>FORXIGA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female between the ages of 18 and 100 years.&#xD;
&#xD;
          2. Elevated NT-proBNP or BNP levels on admission.&#xD;
&#xD;
          3. Ejection fraction of 50% or less, and New York Heart Association (NYHA) class II, III,&#xD;
             or IV symptoms.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treatment with SGLT2-i during the past 3 months of admission,or previous intolerance&#xD;
             of an SGLT2 inhibitor.&#xD;
&#xD;
          2. Severe (eGFR &lt;30 mL/min/1.73 m^2 by CKD-EPI), unstable or rapidly progressing renal&#xD;
             disease at the time of randomization.&#xD;
&#xD;
          3. Pregnant or breast feeding female patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianping Zeng, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Xiangtan Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shenghua Zhou, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Second Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chengming Wang, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>ZhuZhou Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fanghua Xu, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>The First People's Hospital of Xiangtan City</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhiqiang Cai, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Xiangtan People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chonglun Zhou, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Xiangxiang People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianping Zeng, Ph.D.</last_name>
    <phone>+86 15292271982</phone>
    <email>46595842@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xiangtan Central Hospital</name>
      <address>
        <city>Xiangtan</city>
        <state>Hunan</state>
        <zip>411100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianping Zeng, Ph.D.</last_name>
      <phone>+8615292271982</phone>
      <email>46595842@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 31, 2020</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xiangtan Central Hospital</investigator_affiliation>
    <investigator_full_name>Jianping Zeng</investigator_full_name>
    <investigator_title>President of Xiangtan Centeral Hospital</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Anemia</keyword>
  <keyword>Dapagliflozin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

